About: A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses
Creator	Shao, Yiming Xu, Jianguo Wolf, Hans Motz, Manfred Lehmann, Christian Lindner, Petra Zhao, Quanbi
Source	Elsevier; Medline; PMC
abstract	Abstract Most coronaviruses infecting humans cause mild diseases, whereas severe acute respiratory syndrome (SARS)-associated coronavirus is an extremely dangerous pathogen. Here, we report the development of a serologic assay for detection of antibodies to human coronaviruses (HCoVs) based on recombinant nucleocapsid (N) proteins of all known pathogenic strains (229E, NL63, OC43, HKU1, SARS). The novel immunoassay is highly useful for epidemiologic surveys, where use of nucleic acid diagnostics often is limited. Purified recombinant antigens were immobilized on nitrocellulose membranes and applied in a line immunoassay, which allows rapid detection of antibodies to 5 different HCoVs in a single experiment. For assay evaluation, serum samples from persons infected with 229E or OC43 (acute/convalescent), recovered SARS patients and healthy donors were analyzed. Screening for nucleocapsid (N)-specific immunoglobulin G (IgG) in convalescent sera reached 100% sensitivity. With this new technique, we found that recently identified NL63 and HKU1 contribute significantly to the overall spectrum of coronavirus infections. Possibly, cross-reactive antibody responses were observed using 229E and OC43 serum pairs. However, the potential of this assay could clearly be demonstrated employing SARS-positive serum samples, where nonspecific binding to nucleocapsids of other HCoVs was not observed. This coronavirus strain-specific line immunoassay represents a powerful tool for serologic diagnostics.
has issue date	2008-05-31(xsd:dateTime)
bibo:doi	10.1016/j.diagmicrobio.2007.12.002
bibo:pmid	18191362
has license	els-covid
sha1sum (hex)	0a9a85b82e17c880c923b5de9bec22931ed76f13
schema:url	https://doi.org/10.1016/j.diagmicrobio.2007.12.002
resource representing a document's title	A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses
has PubMed Central identifier	PMC7127592
has PubMed identifier	18191362
schema:publication	Diagnostic Microbiology and Infectious Disease
resource representing a document's body	covid:0a9a85b82e17c880c923b5de9bec22931ed76f13#body_text
is schema:about of	named entity 'RECOMBINANT' named entity 'HUMAN' named entity 'donors' named entity 'coronavirus' named entity 'coronaviruses' named entity 'infected' named entity 'antibodies' named entity 'demonstrated' named entity 'serologic' named entity 'pathogen' named entity 'human coronaviruses' named entity 'HEALTHY' named entity 'IMMUNOASSAY' named entity 'NUCLEOCAPSID' named entity 'PATIENTS' named entity 'LIMITED' named entity '100%' named entity 'APPLIED' named entity 'NOT OBSERVED' named entity 'SERUM' named entity 'POWERFUL' named entity 'TOOL' named entity 'INFECTED' named entity 'MEMBRANES' named entity 'DETECTION' named entity 'CONVALESCENT' named entity 'CONTRIBUTE ' named entity 'SARS' named entity 'NITROCELLULOSE' named entity 'PURIFIED' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'DIAGNOSTICS' named entity 'BASED' named entity 'EXPERIMENT' named entity 'NOVEL' named entity 'SAMPLES' named entity 'EVALUATION' named entity 'NEW' named entity 'BINDING' covid:arg/0a9a85b82e17c880c923b5de9bec22931ed76f13 named entity 'IDENTIFIED' named entity 'HUMANS' named entity 'CORONAVIRUSES' named entity 'FOUND' named entity 'ASSOCIATED' named entity 'RECENTLY' named entity 'PATHOGENIC' named entity 'HUMAN' named entity 'DISEASES' named entity 'RESPONSES' named entity 'NL63' named entity 'USE OF' named entity 'STRAIN' named entity 'SENSITIVITY' named entity 'HIGHLY' named entity 'WHERE' named entity 'CORONAVIRUS' named entity 'ASSAY' named entity 'USING' named entity 'SPECIFIC' named entity 'STRAINS' named entity 'A LINE' named entity 'RECOMBINANT' named entity 'PERSONS' named entity 'RECOVERED' named entity 'DONORS' named entity 'KNOWN' named entity 'SERA' named entity 'EXTREMELY' named entity 'NUCLEOCAPSID PROTEINS' named entity 'IMMUNOASSAY' named entity 'A LINE' named entity 'EMPLOYING' named entity 'POTENTIAL' named entity 'IMMUNOGLOBULIN G'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software